Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Has Consensus Price Target of $8.75

Posted by Francis Steltz on Oct 26th, 2026

Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $8.75.

Several equities research analysts have issued reports on PRLD shares. Citigroup reissued a “market outperform” rating on shares of Prelude Therapeutics in a research report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Wednesday, July 29th. Wall Street Zen downgraded shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. JPMorgan Chase & Co. began coverage on shares of Prelude Therapeutics in a research note on Thursday, September 17th. They set an “overweight” rating and a $12.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Prelude Therapeutics in a report on Wednesday, July 29th.

Get Our Latest Research Report on Prelude Therapeutics

Prelude Therapeutics Price Performance

PRLD stock opened at $3.63 on Monday. Prelude Therapeutics has a twelve month low of $1.17 and a twelve month high of $6.83. The firm has a market cap of $289.67 million, a price-to-earnings ratio of -4.97 and a beta of 0.97. The business’s fifty day simple moving average is $4.64 and its two-hundred day simple moving average is $4.54.

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.06. The company had revenue of $5.70 million for the quarter, compared to analysts’ expectations of $5.70 million. Research analysts expect that Prelude Therapeutics will post -0.57 EPS for the current year.

Institutional Investors Weigh In On Prelude Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Prelude Therapeutics during the second quarter valued at approximately $9,581,000. EcoR1 Capital LLC bought a new position in Prelude Therapeutics in the first quarter worth approximately $3,239,000. ADAR1 Capital Management LLC bought a new position in Prelude Therapeutics in the second quarter worth approximately $4,802,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Prelude Therapeutics in the second quarter worth approximately $669,000. Finally, Bank of New York Mellon Corp purchased a new stake in Prelude Therapeutics during the second quarter worth $363,000. 79.72% of the stock is owned by institutional investors.

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics Incorporated is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights into cancer biology to design small-molecule therapies intended to target vulnerabilities in tumor cells while potentially improving selectivity over healthy tissue.

Prelude’s research and development programs have included targeted therapies aimed at cancer-related proteins and signaling pathways, including cyclin-dependent kinase 9 (CDK9) and other regulators of tumor growth and survival.